Skip to main content

Genekor to Distribute Rosetta Genomics' Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has granted exclusive distribution rights in Greece for three of its assays to Genekor, an Athens-based molecular diagnostics firm.

The agreement covers Rosetta's miRview meso, which differentiates lung cancer from mesothelioma; miRview mets, which is designed to determine the source of cancers of unknown primary origin; and miRview squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

Kenneth Berlin, president and CEO of Rehovot, Israel-based Rosetta, noted that the alliance with Genekor is the firm's second distribution deal in Europe, and it plans to expand its distribution network to other European countries this year.

Last year, AXA Diagnostics inked a deal to serve as distributor of the tests in Italy.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.